Eli Lilly released positive results from two late-stage obesity studies showing that patients maintained significant weight loss after switching to either Foundayo or a lower dose of Zepbound. The SURMOUNT-MAINTAIN trial showed continued weight loss maintenance up to week 112, while the ATTAIN-MAINTAIN study confirmed sustained weight reduction with Foundayo. Additionally, Eli Lilly reported strong revenue growth for Mounjaro and Zepbound, driven by high demand despite some price reductions. These findings position Foundayo as a promising alternative to insulin-based treatments for type 2 diabetes patients with obesity or overweight conditions.
The global colorectal cancer diagnostics and therapeutics market is projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching an estimated value of $73 billion by 2034. This growth is driven by rising c...
Eli Lilly's late-phase trials SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN show that adults with obesity maintained most of their weight loss after switching from high doses of injectable therapies Wegovy and Zepbound to either oral Foundayo or lower-dose Z...
Nvidia's market capitalization recently exceeded $5.3 trillion, surpassing the combined value of all 59 healthcare companies in the S&P 500, which total about $5.2 trillion. This shift highlights the massive investor confidence in AI infrastructure, ...
Eli Lilly launched a charitable initiative supporting community organizations to distribute 500,000 nutritious meals across 15 U.S. communities as part of its 150th anniversary. The company also funds cold storage infrastructure for 150 food pantries...
Eli Lilly reported a strong Q1 2026 with revenue up 55.5% to $19.8 billion and earnings per share beating estimates. Its drug Mounjaro became the world's top-selling medication, driving optimism and a raised full-year revenue forecast of $82-$85 bill...
